US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.20

-0.8264-1.33%

Volume:8K

Turnover:486.65K

Market Cap:287.62M

PE:20.02

High:62.20

Open:62.20

Low:60.99

Close:62.02

52wk High:64.10

52wk Low:39.76

Shares:4.70M

Float Shares:4.70M

Volume Ratio:0.22

T/O Rate:0.17%

Dividend:1.53

Dividend Rate:2.49%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)

Recombinant Collagen Leader Faces Growth Challenges After Weak Interim Results

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $260 from $230

THOMSON REUTERS

Brightspring Health Services Inc Stock (BTSG) Closed Up by 7.20% on Aug 26: Key Drivers Unveiled

Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month

MT Newswires Live

Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports

MT Newswires Live

Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call

THOMSON REUTERS

Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

Revolution Medicines announces FDA approval of Rasonque in adults

Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.

THOMSON REUTERS

U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer

THOMSON REUTERS

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

Boston Scientific Hit by Cyberattack, Shares Slide on Delivery Disruption

FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease

Roivant Says JAMA Dermatology Publishes Phase 3 VALOR Data Showing Brepocitinib Improves Dermatomyositis Skin Outcomes

Jama Dermatology Publishes Skin-Specific Outcomes from Phase 3 Valor Trial of Brepocitinib in Dermatomyositis

THOMSON REUTERS

US FDA Approves Revolution Medicines' Pancreatic Cancer Drug

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

THOMSON REUTERS

Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/PTH/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":61.196,"timestamp":1789755798611,"preClose":62.0224,"halted":0,"volume":7937,"delay":0,"changeRate":-0.013324218346919816,"floatShares":4700000,"shares":4700000,"eps":3.057033,"marketStatus":"Trading","change":-0.8264,"latestTime":"09-18 14:24:45 EDT","open":62.1967,"high":62.1967,"low":60.985,"amount":486647.07501,"amplitude":0.019536,"askPrice":61.2,"askSize":300,"bidPrice":61.11,"bidSize":100,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789761600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":62.0224,"sharesOutstanding":2480000,"nav":60.77493,"aum":287465418.9,"dividendRate":0.024931,"bidAskSpread":0.00195,"preHourTrading":{"tag":"盘前","latestPrice":62.0224,"preClose":62.0224,"latestTime":"04:00 EDT","volume":1,"amount":62.0224,"timestamp":1789718420500,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":62.01,"preClose":62.0224,"latestTime":"19:30 EDT","volume":10,"amount":619.8306,"timestamp":1789687804886,"change":-0.0124,"changeRate":-0.0002,"amplitude":0},"volumeRatio":0.216235,"impliedVol":0.0869,"impliedVolPercentile":0.243},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4700000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.216235,"shares":4700000,"dividePrice":1.5257,"high":62.1967,"amplitude":0.019536,"preClose":62.0224,"low":60.985,"week52Low":39.76,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":61.196,"committee":-0.5,"eps":3.057033,"divideRate":0.024931,"volume":7937,"delay":0,"ttmEps":3.057033,"open":62.1967,"prevYearClose":49.701,"prevWeekClose":60.7692,"prevMonthClose":60.7941,"prevQuarterClose":59.76,"fiveDayClose":60.7692,"twentyDayClose":62.111,"sixtyDayClose":55.6532},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662706801","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706801","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662706801?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:30","pubTimestamp":1787826622,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Immuneering (IMRX) w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BBH","XBI","BK4539","LU0128526141.USD","CANC","IE0009355771.USD","LU0109394709.USD","BK4585","PTH","BK4139","XLV","IDNA","IE00B2B36J28.USD","BK4137","IMRX","RVMD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","BK4563","IE0009354923.USD","LU0029874061.USD","BK4588","LU0889565916.HKD","HCSG","IE00BJJMRZ35.SGD","LU0320765992.SGD","LABU","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192894793","title":"Recombinant Collagen Leader Faces Growth Challenges After Weak Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1192894793","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192894793?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:42","pubTimestamp":1787820126,"startTime":"0","endTime":"0","summary":"Jinbo Bio, a leading player in the recombinant collagen sector, recently published its interim report for the first half of 2026, revealing a notable setback in its growth trajectory. The financial...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","09996","LNGR","LGHT","MEDX","GDOC","BK1100","HART","IEIH","AGNG","RSPH","MDEV","PTH","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662988724","title":"Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $260 from $230","url":"https://stock-news.laohu8.com/highlight/detail?id=2662988724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662988724?lang=en_us&edition=fundamental","pubTime":"2026-08-27 10:38","pubTimestamp":1787798329,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44N0VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJJMRZ35.SGD","IE0009354923.USD","BBH","PTH","LU0320765992.SGD","IE0002141913.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","CANC","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IDNA","IE0009355771.USD","RVMD","LU0889565916.HKD","LU0109394709.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662574411","title":"Brightspring Health Services Inc Stock (BTSG) Closed Up by 7.20% on Aug 26: Key Drivers Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2662574411","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662574411?lang=en_us&edition=fundamental","pubTime":"2026-08-27 04:15","pubTimestamp":1787775315,"startTime":"0","endTime":"0","summary":"• BrightSpring reported strong second-quarter revenue and raised its full-year guidance.\n• Wall Street analysts maintained buy ratings with an average price target of $78.97.\n• Annual revenue reached $12.91 billion with a net profit of $190.67 million.","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262133901-market-movers-btsg-20260826","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTSG","PTH","PSCH","LU2468319806.SGD","BK4196","LU2089984988.USD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662749358","title":"Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2662749358","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662749358?lang=en_us&edition=fundamental","pubTime":"2026-08-27 02:20","pubTimestamp":1787768430,"startTime":"0","endTime":"0","summary":"Revolution Medicines'  once-daily oral Rasonque tablets for the treatment of metastatic pancreatic cancer are available in the US at a price of $39,800 for a 30-day supply, the company said Wednesday in a regulatory filing.The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.Price: 215.95, Change: +4.57, Percent Change: +2.16","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IE0009354923.USD","IE0002141913.USD","IE0009355771.USD","IDNA","PTH","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","IE00B2B36J28.USD","BBH","RVMD","IE00BJJMRZ35.SGD","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662746776","title":"Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2662746776","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662746776?lang=en_us&edition=fundamental","pubTime":"2026-08-27 02:02","pubTimestamp":1787767375,"startTime":"0","endTime":"0","summary":"Price: 215.72, Change: +4.34, Percent Change: +2.05","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","IE00B2B36J28.USD","PTH","IE00B4R5TH58.HKD","CANC","RVMD","IE00BJT1NW94.SGD","LU0320765992.SGD","IE00BJJMRZ35.SGD","BK4139","IE0002141913.USD","BBH","IE0009354923.USD","IDNA","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662462057","title":"Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2662462057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662462057?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:56","pubTimestamp":1787766961,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0O4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IE0009354923.USD","IE0002141913.USD","IE0009355771.USD","IDNA","PTH","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","IE00B2B36J28.USD","BBH","RVMD","IE00BJJMRZ35.SGD","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662746411","title":"Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2662746411","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662746411?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:45","pubTimestamp":1787766356,"startTime":"0","endTime":"0","summary":"Revolution Medicines posts investor presentation on RASONQUE FDA approvalRevolution Medicines released an investor presentation covering U.S. FDA approval of RASONQUE (daraxonrasib) for metastatic pan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL4qMXCX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE0009355771.USD","IE00BJT1NW94.SGD","IE0009354923.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU0320765992.SGD","CANC","IE00B4R5TH58.HKD","IDNA","BBH","LU0109394709.USD","BK4139","RVMD","PTH","IE00BFTCPJ56.SGD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797746","title":"Revolution Medicines prices Rasonque at $39,800 for 30-day supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797746?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:45","pubTimestamp":1787766320,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) disclosed that following FDA approval of Rasonque for the treatment of adult patients with metastatic pancreatic adenoc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PTH","IE00BFTCPJ56.SGD","CANC","IDNA","BBP","BK4588","BK4585","FRTY","GDOC","BBH","LU0109394709.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","TBXU","XLVX","BMED","PINK","IYH","LABU","GNMX","IBB","RSPH","RVMD","TECB","IE00B4R5TH58.HKD","MEDI","IE0009355771.USD","NVIB","PSCH","LU0889565916.HKD","IE0009354923.USD","MRNY","LU0320765992.SGD","IEIH","LFSC","IE00B2B36J28.USD","MRNX","IE00BJT1NW94.SGD","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662074659","title":"Revolution Medicines announces FDA approval of Rasonque in adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2662074659","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662074659?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:05","pubTimestamp":1787763925,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration has approved RASONQUE once-daily oral tablets, for the treatment o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYNB","LU0320765992.SGD","IE00B4R5TH58.HKD","IDNA","CANC","LABU","MRNY","GNMX","PTH","XLVX","BMED","MRNX","LU0889565916.HKD","IE0009354923.USD","IBB","BBH","IE00BFTCPJ56.SGD","PINK","RVMD","BBP","IE00BJJMRZ35.SGD","MEDI","IE0002141913.USD","IE00B2B36J28.USD","GDOC","PSCH","IE00BJT1NW94.SGD","NVIB","TBXU","LU0109394709.USD","BK4139","IE0009355771.USD","BK4588","TECB","FRTY","IYH","LFSC","IEIH","RSPH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662745207","title":"Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662745207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662745207?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:59","pubTimestamp":1787763576,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA6XRCYX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CANC","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0320765992.SGD","LU0109394709.USD","IE0009354923.USD","IE00B2B36J28.USD","PTH","IE00BFTCPJ56.SGD","IE0009355771.USD","RVMD","IDNA","BK4139","BBH","LU0889565916.HKD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662452007","title":"U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662452007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662452007?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:59","pubTimestamp":1787763576,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA6XRCYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RVMD","LU0889565916.HKD","IE00B2B36J28.USD","IE0009354923.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE0002141913.USD","PTH","IE0009355771.USD","IE00B4R5TH58.HKD","IDNA","IE00BFTCPJ56.SGD","CANC","LU0320765992.SGD","BK4139","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662759746","title":"U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759746","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662759746?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:59","pubTimestamp":1787763540,"startTime":"0","endTime":"0","summary":"RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent syste","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351615/0/en/u-s-fda-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRET","BK4588","BBH","IE00BZ199S13.USD","PFS","BK4605","IE00B4R5TH58.HKD","LU0109394709.USD","BK4585","LU0889565916.HKD","IE0009354923.USD","BK4141","BK4009","IE00B2B36J28.USD","L","RVMD","LU0724618433.USD","LU0124384867.USD","IE0009355771.USD","LU1861219969.SGD","ONX","LU0053671581.USD","LU2487616109.SGD","IE00BJJMRZ35.SGD","ON","IDNA","LABU","IE00BD6J9T35.USD","BK4023","BK4225","BK4613","ONG","LU1854103824.USD","LU1861220033.SGD","BK4139","CANC","PTH","TTD","LU1720051017.SGD","TTDU","EMA","HR","LU2360107325.USD","LU1720051108.HKD","LU0210528500.USD","LU1978683503.SGD","LU0320765992.SGD","ITT","BK4512","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163553180","title":"Boston Scientific Hit by Cyberattack, Shares Slide on Delivery Disruption","url":"https://stock-news.laohu8.com/highlight/detail?id=1163553180","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163553180?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:30","pubTimestamp":1787758250,"startTime":"0","endTime":"0","summary":"Boston Scientific disclosed in a Wednesday filing with the U.S. Securities and Exchange Commission (SEC) that it has been struck by a cyberattack, impacting its business operations. The incident is...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","LU0345769631.USD","LU1989764664.SGD","MEDX","LU1720051108.HKD","IE0002141913.USD","LU0345769128.USD","LU0528227936.USD","WCBR","LU2362541513.USD","LU0950375773.USD","LU1989772840.SGD","SG9999001176.SGD","AGNG","LU1804176565.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","LU2491050071.SGD","SPAM","09996","LGHT","LU2112291526.USD","BK4504","LU1548497426.USD","LU1718418525.SGD","BK4588","159883","LU0048584097.USD","LU2491049909.HKD","LNGR","LU2362540622.SGD","LU2265009873.SGD","LU0353189763.USD","IEIH","SG9999001176.USD","LU0122379950.USD","LU2242649171.HKD","LU1791710582.SGD","LU0187121727.USD","LU1291159041.SGD","LU2506951958.HKD","BK4581","GDOC","MDEV","BK1574","BK4082","LU2362541273.HKD","UCYB","LU2506952097.USD","LU0823417737.USD","LU2244417387.USD","LU0238689110.USD","SGXZ57979304.SGD","IE00B2B36J28.USD","LU2087625088.SGD","LU2506951875.HKD","LU1061106388.HKD","LU1791710400.SGD","SG9999013999.USD","BSX","LU0267386448.USD","LU0114720955.EUR","RSPH","LU1983299246.USD","LU0077335932.USD","IE00BJJMRZ35.SGD","BK1583","LU1989771016.USD","HAKY","LU0266013472.USD","LU0823417653.USD","IE00BJT1NW94.SGD","BK4585","LU0251132253.USD","LU1720051017.SGD","HART","LU2491050154.USD","LU0353189680.USD","LU0138981039.USD","LU0011850046.USD","LU2506952170.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","PTH","LU0432979614.USD","LU0882574055.USD","LU2324357040.USD","BK1100","LU1989764748.USD","LU0823416689.USD","LU1366192091.USD","LU2357305700.SGD","LU1153585028.USD","LU0225283273.USD","LU1989772923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662748785","title":"FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2662748785","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662748785?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:18","pubTimestamp":1787757480,"startTime":"0","endTime":"0","summary":"For four decades, cancer researchers fought to disable a stubborn mutation that made pancreatic cancer a death sentence-to little avail.Now, doctors have a medicine that targets the mutation. The Food","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","IE0002141913.USD","IE00B4R5TH58.HKD","BK6515","PTH","LU0889565916.HKD","IE00B2B36J28.USD","BBH","BK4588","IE0009355771.USD","IE0009354923.USD","RDR.SI","BK4139","LABU","IE00BJJMRZ35.SGD","BK6027","LU0109394709.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0320765992.SGD","BK4585","RVMD","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662748478","title":"Roivant Says JAMA Dermatology Publishes Phase 3 VALOR Data Showing Brepocitinib Improves Dermatomyositis Skin Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2662748478","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662748478?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:12","pubTimestamp":1787757130,"startTime":"0","endTime":"0","summary":"Roivant says JAMA Dermatology publishes Phase 3 VALOR data showing brepocitinib improves dermatomyositis skin outcomesRoivant reported a JAMA Dermatology publication of skin-focused Phase 3 VALOR resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL4G7BRP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","SG9999014013.SGD","PTH","NDAQ","BK4007","SG9999014005.SGD","IE00BQXX3F31.USD","BK4112","IE00BKPKM429.USD","BK4588","LU2095319765.USD","SG9999014039.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","BCDF","IE00BN0W2V16.EUR","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","LU2210149790.SGD","ROIV","IE00B64PRP62.GBP","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662441748","title":"Jama Dermatology Publishes Skin-Specific Outcomes from Phase 3 Valor Trial of Brepocitinib in Dermatomyositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2662441748","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662441748?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:11","pubTimestamp":1787757107,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA2RQXQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4007","BK4139","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662107077","title":"US FDA Approves Revolution Medicines' Pancreatic Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662107077","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662107077?lang=en_us&edition=fundamental","pubTime":"2026-08-26 22:43","pubTimestamp":1787755405,"startTime":"0","endTime":"0","summary":"US FDA approves Revolution Medicines' pancreatic cancer drugAug 26 (Reuters)-The U.S. Food and Drug Administration approved Revolution Medicines'RVMD.Otargeted drug for metastatic pancreatic cancer, the regulator said on Wednesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4N44N16Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE0002141913.USD","IE0009355771.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","PTH","CANC","IDNA","LU0109394709.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","BBH","IE0009354923.USD","BK4139","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662102887","title":"FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662102887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662102887?lang=en_us&edition=fundamental","pubTime":"2026-08-26 22:38","pubTimestamp":1787755107,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N110:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RVMD","LU0889565916.HKD","IE00B2B36J28.USD","IE0009354923.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE0002141913.USD","PTH","IE0009355771.USD","IE00B4R5TH58.HKD","IDNA","IE00BFTCPJ56.SGD","CANC","LU0320765992.SGD","BK4139","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662502718","title":"Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662502718","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662502718?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:52","pubTimestamp":1787741522,"startTime":"0","endTime":"0","summary":"Revolution Medicines CEO Mark A. Goldsmith reports disposal of common shares worth $16.87 millionRevolution Medicines CEO Mark A. Goldsmith exercised stock options for 80,000 shares at USD 4.73 on Aug","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL5Nrx4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0889565916.HKD","IE0002141913.USD","CANC","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4139","PTH","BBH","IE00BJT1NW94.SGD","LU0109394709.USD","RVMD","IDNA","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}